Price T Rowe Associates Inc Cogent Biosciences, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 35,211 shares of COGT stock, worth $297,180. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,211
Previous 31,181
12.92%
Holding current value
$297,180
Previous $184,000
28.8%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding COGT
# of Institutions
159Shares Held
102MCall Options Held
197KPut Options Held
102K-
Kynam Capital Management, LP Princeton, NJ8.5MShares$71.7 Million5.99% of portfolio
-
State Street Corp Boston, MA7.63MShares$64.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.69MShares$56.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.68MShares$56.3 Million0.11% of portfolio
-
Commodore Capital LP New York, NY6.43MShares$54.2 Million3.73% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $555M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...